FDA Forms Nanotechnology Task Force To Assess Technology
This article was originally published in The Rose Sheet
Executive Summary
FDA's Nanotechnology Task Force will identify policy gaps related to the use of nanotechnology particles to evaluate possible adverse health effects from products that contain the materials, the agency said
You may also be interested in...
Nanotechnology Regulation Limited By FDA Budget Constraints – Report
FDA's budget constraints and gaps in its legal authority hinder its ability to understand and manage nanotechnology's potential risks, according to Michael Taylor, a professor at the University of Maryland School of Medicine who formerly served as deputy commissioner for policy at FDA
Nanotechnology Regulation Limited By FDA Budget Constraints – Report
FDA's budget constraints and gaps in its legal authority hinder its ability to understand and manage nanotechnology's potential risks, according to Michael Taylor, a professor at the University of Maryland School of Medicine who formerly served as deputy commissioner for policy at FDA
FDA nanotech meeting
Agency will sponsor public meeting in mid-October on nanotechnology, FDA announces in April 13 Federal Register notice. Topics slated to be discussed include types of nanotechnology material products under development in the areas of cosmetics, foods, drugs and other FDA-regulated areas. Meeting also provides opportunity to evaluate "whether there are scientific issues that should be addressed; and any other issues about which the regulated industry, academia and the interested public may wish to inform FDA" concerning nanotechnology use, FDA notes. Details regarding date and time of meeting, which will be held in Washington, D.C., will be provided in a subsequent Federal Register notice, agency adds...